Cumulus Oncology Strengthens Board of Directors & Scientific Advisory Team
Appoints Dr Manuel Aivado as Director and Dr Brian Jones as Scientific Advisor
EDINBURGH, Scotland, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cumulus Oncology, an oncology and inflammation focused biotech, announces the expansion of its Board of Directors (BoD) and scientific advisory team with the appointment of Dr Manuel Aivado to the BoD and the appointment of Dr Brian Jones as a Scientific Advisor.
Manuel Aivado, MD PhD, is a board-certified haematologist and oncologist with extensive experience in the pharma and biotech drug development field. He brings deep insights into the key features driving successful drug approvals, including the evaluation of unmet medical need. Manuel has been integrally involved in the strategic and operational aspects of six new drug approvals (NDAs), including four in oncology, in recent years. Manuel has a strong track record in successful clinical development strategies as well as successful business management based on his operational experience steering and guiding other private and public companies as an Executive or Board Director.
Commenting on his appointment, Dr Manuel Aivado, said, “Having observed the exceptional calibre of the Board, the operational team, and the asset pipeline at Cumulus, the synergies between my own perspective regarding what makes for a successful development strategy and the aspirations of the Cumulus team is truly inspiring. I am honoured to join the Board as the Non-Executive Director appointed by one of our key investors, the Scottish National Investment Bank. I look forward to supporting the company as it works to advance the clinical development of its internal pipeline assets in order to achieve key value inflection milestones while also strengthening the company’s capabilities to acquire competitive assets.”
The company is also expanding its scientific team with the appointment of Dr Brian Jones as a Scientific Advisor. Brian is a PhD chemist with extensive experience of successful small molecule drug discovery and development in both pharma and biotech. He has deep expertise and insights across a range of therapeutic areas and novel target space, and he will support the progression of the company’s existing portfolio as well as enhancing the company’s ability to identify novel asset acquisition targets.
“Having enjoyed the opportunity to work with the scientific operations team at Cumulus in 2024, I have been following the company closely and have seen positive progress and the emergence of high-quality data. I therefore jumped at the opportunity to join as a Scientific Advisor. I have already been involved in a deep scientific dive on one of Cumulus’s key programmes to enable a positive decision to move forward to the next value-creating milestone. I admire that the team has a laser focus on scientific integrity coupled with clear patient need and commercial opportunity and that they embed data-driven decision making into their modus operandi.” Dr Jones said.
Cumulus’s chairman of the board, Dr Brian Gallagher, commented, “We are delighted to welcome Brian Jones and Manuel to the Cumulus team. I’m delighted to work with Manuel again on another exciting oncology startup. I have always been impressed with his passion for making a difference in areas of unmet medical need. His extensive experience as a board member, and chair, for several biotechs in the US and Switzerland will be a superb asset.” Dr Gallagher added, “Brian Jones made an excellent contribution when working with our scientific operations team last year, and it’s now a great win for us to have him on board as a Scientific Advisor. I am really looking forward to working with both of our new team members.”
Dr Clare Wareing, Founder & CEO of Cumulus Oncology, added, “I’m also greatly looking forward to working with Manuel and Brian on our mission to accelerate oncology innovation into world changing impact. Both are active members of the Boston biotech ecosystem, where we see significant potential for collaborations. These top-class appointments add momentum to our ongoing portfolio and asset acquisition activities to ensure only assets with the highest chance of commercial success are taken forward.”
In the last 12 months, the company has made significant progress on several key programmes and expects to share key data updates by the end of the year, including in vivo proof-of-concept results in oncology and inflammation indications.
About Cumulus Oncology
Cumulus Oncology is developing a portfolio of assets targeting known and novel pathways in oncology and inflammation. The company creates novel oncology asset opportunities via its internal ideation function, supplemented by asset ID and acquisition from a range of sources including academic institutes, commercial drug discovery groups, and biopharmaceutical companies. An early focus on molecularly selected patient sub-groups is a key aspect of the company’s strategic focus. The company incorporates the use of a range of tools including artificial intelligence (AI) and machine learning (ML) platforms into its decision-making process to prioritize targets and assets and build patient sub-group hypotheses.
Cumulus currently has a portfolio of four assets focused in areas of high scientific validation and active pharma company deal activity. This includes assets in the DDR area, a focus on GPCRs in the oncology and inflammation areas, as well as novel targets and assets within well-defined pathways where both a precision medicine approach and clinical proof of concept exist.
The founding team at Cumulus consists of successful life science entrepreneurs, scientists, and a range of oncology drug development and pharma sector business professionals who have collectively taken ten oncology assets to successful drug approval.
For more information on Cumulus Oncology, visit CumulusOncology.com and connect on LinkedIn.
Media Inquiries
Cumulus Oncology
Clare Wareing, CEO
Scius Communications
Katja Stout
Tel: +44 7789 435 990
Daniel Gooch
Tel: +44 7747 875 479
daniel@sciuscommunications.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
